- Dexcom plans a €300 million investment over five years in Galway.
- The project aims to create up to 1,000 high-skilled jobs.
- The facility will focus on automated, green technologies.
- Subject to planning approval, the site will be on IDA Ireland's landbank in Athenry.
Investment and Job Creation
Dexcom, a leader in continuous glucose monitoring, plans to invest €300 million over five years to build a new manufacturing facility in Athenry, Galway. This project, supported by the Irish Government through IDA Ireland, is expected to create up to 1,000 high-skilled jobs over the same period.
Government Support
Taoiseach Leo Varadkar highlighted the significant impact on local employment and the economy, noting that this will be one of the largest private sector investments in the West of Ireland. Minister for Enterprise, Trade and Employment Simon Coveney emphasized the boost to the West, MidWest, and Midlands regions, citing Ireland's growing talent pool and MedTech cluster.
Facility Details
Subject to planning permission, the Athenry site will be Dexcom’s first manufacturing facility in Europe, complementing existing operations in the U.S. and Malaysia. The facility will focus on producing millions of CGM sensors annually, incorporating highly automated and green technologies. Approximately 500 construction jobs will be created during the build phase, with up to 1,000 high-tech positions available once operational.
Strategic Importance
Barry Regan, Executive Vice President of Global Operations at Dexcom, stated that the new facility is part of an ambitious growth strategy to support the expanding European user base. Michael Lohan, CEO of IDA Ireland, noted that this investment underscores Ireland’s strong track record in attracting major MedTech investments.
